Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
OtherMinireview

Adverse Drug Reactions and Toxicity of the FDA-approved Antisense Oligonucleotide Drugs

Feryal Alhamadani, Kristy Zhang, Rajvi Parikh, Hangyu Wu, Theodore P Rasmussen, Raman Bahal, Xiao-bo Zhong and Jose E. Manautou PhD
Drug Metabolism and Disposition February 27, 2022, DMD-MR-2021-000418; DOI: https://doi.org/10.1124/dmd.121.000418
Feryal Alhamadani
1University of Connecticut, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kristy Zhang
1University of Connecticut, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rajvi Parikh
1University of Connecticut, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hangyu Wu
1University of Connecticut, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Theodore P Rasmussen
1University of Connecticut, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raman Bahal
1University of Connecticut, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiao-bo Zhong
2Pharmaceutical Sciences, University of Connecticut, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Xiao-bo Zhong
  • For correspondence: jose.manautou@uconn.edu
Jose E. Manautou PhD
2Pharmaceutical Sciences, University of Connecticut, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jose.manautou@uconn.edu
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Information

DMD-MR-2021-000418
DOI 
https://doi.org/10.1124/dmd.121.000418
PubMed 
35221289

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0090-9556
Online ISSN 
1521-009X
History 
  • Published online February 27, 2022.

Article Versions

  • You are currently viewing an Earlier version of this article (February 27, 2022 - 05:05).
  • View the most recent version of this article
Copyright & Usage 
Copyright © 2020 American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Feryal Alhamadani1,
  2. Kristy Zhang1,
  3. Rajvi Parikh1,
  4. Hangyu Wu1,
  5. Theodore P Rasmussen1,
  6. Raman Bahal1,
  7. Xiao-bo Zhong2,*, and
  8. Jose E. Manautou PhD2,*
  1. 1University of Connecticut, United States
  2. 2Pharmaceutical Sciences, University of Connecticut, United States
  1. ↵* Corresponding Author:
    Jose E. Manautou, Pharmaceutical Sciences, University of Connecticut, Department of Pharmaceutical Sciences, University of Connecticut, 69 North Eagleville Road Unit 3092, Storrs, Connecticut, 06269-3092, United States. E-mail: jose.manautou{at}uconn.edu
  2. * Corresponding Author; email: xiaobo.zhong{at}uconn.edu

Statistics from Altmetric.com

Article usage

Article usage: February 2022 to March 2023

AbstractFullPdf
Feb 2022182456
Mar 20228918431
Apr 20224240327
May 20224340271
Jun 2022561108244
Jul 2022184327260
Aug 2022137320194
Sep 2022156290251
Oct 2022178194229
Nov 2022182191243
Dec 2022117136157
Jan 2023183180205
Feb 202357937117
Mar 20234302778

Next
Back to top

In this issue

Drug Metabolism and Disposition: 51 (3)
Drug Metabolism and Disposition
Vol. 51, Issue 3
1 Mar 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Adverse Drug Reactions and Toxicity of the FDA-approved Antisense Oligonucleotide Drugs
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherMinireview

Safety of Antisense Oligonucleotide Drugs

Feryal Alhamadani, Kristy Zhang, Rajvi Parikh, Hangyu Wu, Theodore P Rasmussen, Raman Bahal, Xiao-bo Zhong and Jose E. Manautou
Drug Metabolism and Disposition February 27, 2022, DMD-MR-2021-000418; DOI: https://doi.org/10.1124/dmd.121.000418

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherMinireview

Safety of Antisense Oligonucleotide Drugs

Feryal Alhamadani, Kristy Zhang, Rajvi Parikh, Hangyu Wu, Theodore P Rasmussen, Raman Bahal, Xiao-bo Zhong and Jose E. Manautou
Drug Metabolism and Disposition February 27, 2022, DMD-MR-2021-000418; DOI: https://doi.org/10.1124/dmd.121.000418
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • P450s in the eye
  • Fifty years of AHR research in the pages of DMD
  • Activation/ inactivation of anticancer drugs by CYP3A4
Show more Minireview

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics